$727 Million is the total value of Kynam Capital Management, LP's 26 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 64.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Sell | NATERA INC | $141,114,000 | -12.9% | 2,900,000 | -0.6% | 19.41% | -7.2% |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $48,150,000 | +84.0% | 3,000,000 | -11.0% | 6.62% | +96.0% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $26,937,731 | -14.8% | 975,298 | -29.1% | 3.70% | -9.2% |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $22,344,653 | -36.5% | 1,454,730 | -7.0% | 3.07% | -32.3% |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $11,778,118 | +68.7% | 1,304,332 | -35.2% | 1.62% | +79.8% |
| CNTB | Sell | CONNECT BIOPHARMA HLDGS LTDads | $602,640 | -18.5% | 535,005 | -27.7% | 0.08% | -12.6% |
| MRUS | Exit | MERUS N V | $0 | – | -21,457 | -100.0% | -0.05% | – |
| Exit | ARCELLX INC | $0 | – | -31,336 | -100.0% | -0.12% | – | |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -28,696 | -100.0% | -0.13% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -1,502,866 | -100.0% | -0.24% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -768,913 | -100.0% | -0.56% | – |
| ALLO | Exit | ALLOGENE THERAPEUTICS INC | $0 | – | -1,495,981 | -100.0% | -0.95% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -1,800,000 | -100.0% | -1.42% | – |
| Exit | GSK PLCsponsored adr | $0 | – | -498,329 | -100.0% | -2.29% | – | |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -499,853 | -100.0% | -2.40% | – |
| SGEN | Exit | SEAGEN INC | $0 | – | -100,000 | -100.0% | -2.61% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -1,094,620 | -100.0% | -15.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.